Zymeworks Inc reports results for the quarter ended in December - Earnings Summary

Zymeworks

06/03/2024 23:18

* Zymeworks Inc  ZYME.OQ  reported a quarterly adjusted loss
of 20
cents​​ per share for the quarter ended in December, lower than
the same quarter last year, when the company reported EPS of
$4.65.  The mean expectation of seven analysts for the quarter
was for a loss of 43 cents per share. Wall Street expected
results to range from -69 cents to -23 cents per share.
    * Revenue fell 95.8% to $16.93 million from a year ago;
analysts
expected $15.45 million. 
    * Zymeworks Inc's reported EPS for the quarter was a loss
of 20
cents​.
    * The company reported a quarterly loss of $14.48 million.
    * Zymeworks Inc shares had risen by 15.3% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 8.2%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Zymeworks Inc is
$12.50 
This summary was machine generated from LSEG data March 6 at
11:17 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.43          -0.20          Beat
 Sep. 30 2023      -0.47          -0.41          Beat
 Jun. 30 2023      -0.47          -0.76          Missed
 Mar. 31 2023      -0.54          -0.36          Beat